Literature DB >> 33545063

Mutant p53 suppresses innate immune signaling to promote tumorigenesis.

Monisankar Ghosh1, Suchandrima Saha1, Julie Bettke2, Rachana Nagar1, Alejandro Parrales3, Tomoo Iwakuma3, Adrianus W M van der Velden2, Luis A Martinez4.   

Abstract

Mutant p53 (mtp53) proteins can exert cancer-promoting gain-of-function activities. We report a mechanism by which mtp53 suppresses both cell-autonomous and non-cell-autonomous signaling to promote cancer cell survival and evasion of tumor immune surveillance. Mtp53 interferes with the function of the cytoplasmic DNA sensing machinery, cGAS-STING-TBK1-IRF3, that activates the innate immune response. Mtp53, but not wild-type p53, binds to TANK-binding protein kinase 1 (TBK1) and prevents the formation of a trimeric complex between TBK1, STING, and IRF3, which is required for activation, nuclear translocation, and transcriptional activity of IRF3. Inactivation of innate immune signaling by mtp53 alters cytokine production, resulting in immune evasion. Restoring TBK1 signaling is sufficient to bypass mtp53 and lead to restored immune cell function and cancer cell eradication. This work is of translational interest because therapeutic approaches that restore TBK1 function could potentially reactivate immune surveillance and eliminate mtp53 tumors.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IRF3; STING; TBK1; immune evasion; innate immune signaling; mutant p53

Mesh:

Substances:

Year:  2021        PMID: 33545063      PMCID: PMC8044023          DOI: 10.1016/j.ccell.2021.01.003

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  48 in total

1.  Genomic instability and apoptosis are frequent in p53 deficient young mice.

Authors:  K Fukasawa; F Wiener; G F Vande Woude; S Mai
Journal:  Oncogene       Date:  1997-09       Impact factor: 9.867

2.  Genome-scale CRISPR-Cas9 knockout screening in human cells.

Authors:  Ophir Shalem; Neville E Sanjana; Ella Hartenian; Xi Shi; David A Scott; Tarjei Mikkelson; Dirk Heckl; Benjamin L Ebert; David E Root; John G Doench; Feng Zhang
Journal:  Science       Date:  2013-12-12       Impact factor: 47.728

3.  Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer.

Authors:  Winifred Lo; Maria Parkhurst; Paul F Robbins; Eric Tran; Yong-Chen Lu; Li Jia; Jared J Gartner; Anna Pasetto; Drew Deniger; Parisa Malekzadeh; Thomas E Shelton; Todd Prickett; Satyajit Ray; Scott Kivitz; Biman C Paria; Isaac Kriley; David S Schrump; Steven A Rosenberg
Journal:  Cancer Immunol Res       Date:  2019-02-01       Impact factor: 11.151

4.  Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling.

Authors:  Susann Weissmueller; Eusebio Manchado; Michael Saborowski; John P Morris; Elvin Wagenblast; Carrie A Davis; Sung-Hwan Moon; Neil T Pfister; Darjus F Tschaharganeh; Thomas Kitzing; Daniela Aust; Elke K Markert; Jianmin Wu; Sean M Grimmond; Christian Pilarsky; Carol Prives; Andrew V Biankin; Scott W Lowe
Journal:  Cell       Date:  2014-04-10       Impact factor: 41.582

5.  Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation.

Authors:  Siqi Liu; Xin Cai; Jiaxi Wu; Qian Cong; Xiang Chen; Tuo Li; Fenghe Du; Junyao Ren; You-Tong Wu; Nick V Grishin; Zhijian J Chen
Journal:  Science       Date:  2015-01-29       Impact factor: 47.728

Review 6.  Mutant p53 partners in crime.

Authors:  Michael P Kim; Guillermina Lozano
Journal:  Cell Death Differ       Date:  2017-11-03       Impact factor: 15.828

7.  IFI16 is required for DNA sensing in human macrophages by promoting production and function of cGAMP.

Authors:  K L Jønsson; A Laustsen; C Krapp; K A Skipper; K Thavachelvam; D Hotter; J H Egedal; M Kjolby; P Mohammadi; T Prabakaran; L K Sørensen; C Sun; S B Jensen; C K Holm; R J Lebbink; M Johannsen; M Nyegaard; J G Mikkelsen; F Kirchhoff; S R Paludan; M R Jakobsen
Journal:  Nat Commun       Date:  2017-02-10       Impact factor: 14.919

Review 8.  Inflammatory signaling in genomically instable cancers.

Authors:  Francien Talens; Marcel A T M Van Vugt
Journal:  Cell Cycle       Date:  2019-07-10       Impact factor: 4.534

9.  Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages.

Authors:  Aya Kakizaki; Taku Fujimura; Sadanori Furudate; Yumi Kambayashi; Takeshi Yamauchi; Hideo Yagita; Setsuya Aiba
Journal:  Oncoimmunology       Date:  2015-05-26       Impact factor: 8.110

Review 10.  STING: infection, inflammation and cancer.

Authors:  Glen N Barber
Journal:  Nat Rev Immunol       Date:  2015-12       Impact factor: 53.106

View more
  38 in total

1.  Mutant p53 chills tumours by turning off cGAS.

Authors:  Yvonne Bordon
Journal:  Nat Rev Immunol       Date:  2021-03       Impact factor: 53.106

2.  Discovering dominant tumor immune archetypes in a pan-cancer census.

Authors:  Alexis J Combes; Bushra Samad; Jessica Tsui; Nayvin W Chew; Peter Yan; Gabriella C Reeder; Divyashree Kushnoor; Alan Shen; Brittany Davidson; Andrea J Barczak; Michael Adkisson; Austin Edwards; Mohammad Naser; Kevin C Barry; Tristan Courau; Taymour Hammoudi; Rafael J Argüello; Arjun Arkal Rao; Adam B Olshen; Cathy Cai; Jenny Zhan; Katelyn C Davis; Robin K Kelley; Jocelyn S Chapman; Chloe E Atreya; Amar Patel; Adil I Daud; Patrick Ha; Aaron A Diaz; Johannes R Kratz; Eric A Collisson; Gabriela K Fragiadakis; David J Erle; Alexandre Boissonnas; Saurabh Asthana; Vincent Chan; Matthew F Krummel
Journal:  Cell       Date:  2021-12-27       Impact factor: 41.582

Review 3.  Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment.

Authors:  Giulia Petroni; Aitziber Buqué; Lisa M Coussens; Lorenzo Galluzzi
Journal:  Nat Rev Drug Discov       Date:  2022-03-15       Impact factor: 84.694

4.  Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma.

Authors:  Sunetra Das; Rupa Idate; Daniel P Regan; Jared S Fowles; Susan E Lana; Douglas H Thamm; Daniel L Gustafson; Dawn L Duval
Journal:  Commun Biol       Date:  2021-10-11

Review 5.  p73 isoforms meet evolution of metastasis.

Authors:  Stella Logotheti; Athanasia Pavlopoulou; Stephan Marquardt; Işıl Takan; Alexandros G Georgakilas; Thorsten Stiewe
Journal:  Cancer Metastasis Rev       Date:  2022-08-11       Impact factor: 9.237

6.  TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment.

Authors:  Martino Maddalena; Giuseppe Mallel; Nishanth Belugali Nataraj; Michal Shreberk-Shaked; Ori Hassin; Saptaparna Mukherjee; Sharathchandra Arandkar; Ron Rotkopf; Abby Kapsack; Giuseppina Lambiase; Bianca Pellegrino; Eyal Ben-Isaac; Ofra Golani; Yoseph Addadi; Emma Hajaj; Raya Eilam; Ravid Straussman; Yosef Yarden; Michal Lotem; Moshe Oren
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-08       Impact factor: 11.205

7.  MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma.

Authors:  Bastian Krenz; Anneli Gebhardt-Wolf; Carsten P Ade; Abdallah Gaballa; Florian Roehrig; Emilia Vendelova; Apoorva Baluapuri; Ursula Eilers; Peter Gallant; Luana D'Artista; Armin Wiegering; Georg Gasteiger; Mathias T Rosenfeldt; Stefan Bauer; Lars Zender; Elmar Wolf; Martin Eilers
Journal:  Cancer Res       Date:  2021-06-18       Impact factor: 12.701

Review 8.  The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy.

Authors:  Maurice Michel; Leonard Kaps; Annett Maderer; Peter R Galle; Markus Moehler
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

9.  PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models.

Authors:  Thomas Wilson; Giacomo Pirovano; Gu Xiao; Zachary Samuels; Sheryl Roberts; Tara Viray; Navjot Guru; Pat Zanzonico; Marc Gollub; Naga Vara Kishore Pillarsetty; Thomas Reiner; Jill Bargonetti
Journal:  Mol Pharm       Date:  2021-07-28       Impact factor: 5.364

10.  The clinical and molecular significance associated with STING signaling in breast cancer.

Authors:  Eileen E Parkes; Matthew P Humphries; Elaine Gilmore; Fatima A Sidi; Victoria Bingham; Su M Phyu; Stephanie Craig; Catherine Graham; Joseph Miller; Daryl Griffin; Manuel Salto-Tellez; Stephen F Madden; Richard D Kennedy; Samuel F Bakhoum; Stephen McQuaid; Niamh E Buckley
Journal:  NPJ Breast Cancer       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.